Future of R/R DLBCL
A panel of experts discuss the future of R/R DLBCL treatment and review some recent data from the 2022 ASH meeting.
Potential Role of CAR T-cell Therapy in the Front-line Setting for Patients with R/R DLBCL
Experts discuss the potential use of CAR T-cell therapy in the front line setting as well as reviewing the use of tafasitamab from the FRONT-MIND and FIRST-MIND trials.
Sequencing Therapies in Patients with R/R DLBCL
Insightful discussion among a panel of oncologists on how to best sequence therapies for patients with R/R DLBCL.
ZUMA-7: Clinical Implications
Experts review some of the safety outcomes from the ZUMA-7 trial as well as discussing the clinical implications of the ZUMA-7 trial into their practice.
Eligibility Criteria for CAR T-Cell Therapy in R/R DLBCL
An overview of the ZUMA-7 and the TRANSFORM trial as well as reviewing eligibility criteria for patients who might receive CAR-T therapy.
Role of CAR T-cell Therapy in Patients with R/R DLBCL
Panel of experts discuss where CAR T-cell therapy might fit into the treatment landscape for patients with R/R DLBCL.
L-MIND: Review of Long-Term Analyses Data
Comprehensive insight into the L-MIND trial including a review of efficacy outcomes as well as discussing the implications of the data into clinical practice.
Treatment Options for Patients with R/R DLBCL
Experts discuss which factors are considered when choosing treatment options for patients with R/R DLBCL as well as reviewing the mechanism of tafasitamab.
An Overview of R/R DLBCL
Insightful discussion among experts into a brief overview of relapsed/refractory DLBCL (R/R DLBCL).
Front-Line Treatment Options for Patients with DLBCL
Expert oncologists provide a brief overview of front-line treatment options for patients diagnosed with double large b-cell lymphoma (DLBCL).
Unpacking Data in Multiple Myeloma, Non-Hodgkin Lymphoma, and GVHD: Drs Noopur Raje, Joshua Brody, and Ryotaro Nakamura
In this episode, OncLive® speaks with Dr. Noopur Raje on developments in multiple myeloma, Dr. Ryotaro Nakamura on data related to graft-vs-host disease, and Dr. Joshua Brody on the latest in non-Hodgkin lymphoma.
Dr. Brody on Updated Data From the ECHELON-1 Trial in Hodgkin Lymphoma
Joshua Brody, MD, discusses key follow-up data from the phase 3 ECHELON-1 trial in classical Hodgkin lymphoma.
Dr. Brody on Second-Line CAR T-cell Therapy in DLBCL
Joshua Brody, MD, discusses the significance of CAR T-cell therapies being used in earlier treatment lines in patients with diffuse large B-cell lymphoma who relapse within their first year of receiving chemotherapy.
Dr. Brody on the Role of Immunotherapy in Hodgkin Lymphoma
Joshua Brody, MD, discusses the role of immunotherapy in Hodgkin lymphoma.
Dr. Brody on the Expanding Role of Venetoclax in MCL
Joshua Brody, MD, discusses the expanding role of venetoclax in mantle cell lymphoma.
Dr. Brody on Managing CAR T-Cell Therapy Toxicities in MCL
Joshua Brody, MD, discusses management strategies for the toxicities associated with CAR T-cell therapy in mantle cell lymphoma.
Dr. Brody on the Potential Role for Bispecific Antibodies in MCL
Joshua Brody, MD, discusses the potential role for bispecific antibodies in mantle cell lymphoma.
Dr. Brody on the Challenges of Antigen Escape in MCL
Joshua Brody, MD, discusses the challenges of mitigating antigen escape in mantle cell lymphoma.
Dr. Brody on Modulating Fas Signaling to Prevent Relapse in Hematologic Malignancies
Joshua Brody, MD, discusses Fas and its impact on bystander killing in patients with non-Hodgkin lymphoma.
Dr. Brody on Addressing Acquired Resistance to Immunotherapy in Non-Hodgkin Lymphoma
Joshua Brody, MD, discusses addressing required resistance to immunotherapy in non-Hodgkin lymphoma.
Dr. Brody on the Role of Immunotherapy in Indolent Lymphomas
Joshua Brody, MD, discusses the role of immunotherapy in indolent lymphomas.
Dr. Brody on Tolerability of In-Situ Vaccines in Indolent Non-Hodgkin Lymphoma
Joshua Brody, MD, discusses the utility of in-situ vaccines as a novel way to harness immune response and extend the reach of immunotherapy in patients with advanced-stage indolent non-Hodgkin lymphoma.
Dr. Brody on In Situ Vaccinations for Hematologic Cancers
Joshua Brody, MD, discusses the development of in situ vaccinations, a vaccine that is created at the tumor site in patients with cancer.
Dr. Brody Discusses Exciting Therapies for Lymphomas and CLL
Joshua Brody, MD, assistant professor, Icahn School of Medicine, director, Lymphoma Immunotherapy Program, Mount Sinai Hospital, discusses exciting new therapies for lymphomas and chronic lymphocytic leukemia (CLL).
Novel Vaccine Induces Durable Remissions in Patients With Advanced Lymphoma
Immunotherapy can induce regressions of even advanced stage cancers, and many of these patients can have prolonged disease remissions.
Later-Line Ruxolitinib Use Produces Ongoing Benefit in Real-World Patients With cGVHD
Orca-T Data With Survival, Tolerability Extends to Older Patients With Hematologic Cancers
Dr Ramdial on Gemcitabine/Clofarabine/Busulfan for Lymphoma Stem Cell Transplant
Retrospective Analysis Shows Post-HCT Survival Benefits With Orca-T Vs PTCy in Hematologic Malignancies
2 Commerce Drive Cranbury, NJ 08512